SG Americas Securities LLC Buys Shares of 15,457 Inozyme Pharma, Inc. (NASDAQ:INZY)

SG Americas Securities LLC purchased a new position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 15,457 shares of the company’s stock, valued at approximately $81,000.

Other hedge funds have also made changes to their positions in the company. Values First Advisors Inc. bought a new position in Inozyme Pharma during the 2nd quarter worth $76,000. Samlyn Capital LLC grew its position in shares of Inozyme Pharma by 15.0% during the second quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock worth $14,943,000 after acquiring an additional 437,622 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Inozyme Pharma by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,427 shares of the company’s stock worth $96,000 after acquiring an additional 2,690 shares during the period. Affinity Asset Advisors LLC lifted its position in Inozyme Pharma by 8.1% in the 2nd quarter. Affinity Asset Advisors LLC now owns 2,856,252 shares of the company’s stock valued at $12,739,000 after purchasing an additional 213,733 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Inozyme Pharma by 117.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock valued at $1,695,000 after purchasing an additional 205,417 shares during the period. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Stock Down 0.2 %

Shares of INZY stock opened at $4.78 on Tuesday. Inozyme Pharma, Inc. has a 1 year low of $2.70 and a 1 year high of $7.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 9.84 and a current ratio of 9.84. The business’s fifty day moving average is $5.29 and its 200-day moving average is $4.95. The stock has a market cap of $299.85 million, a PE ratio of -3.27 and a beta of 1.51.

Inozyme Pharma (NASDAQ:INZY) last released its earnings results on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). Equities analysts expect that Inozyme Pharma, Inc. will post -1.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

INZY has been the topic of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 price target (up previously from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Inozyme Pharma in a research note on Friday. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a research note on Friday. Stifel Nicolaus began coverage on Inozyme Pharma in a report on Thursday, September 12th. They set a “buy” rating and a $16.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Inozyme Pharma in a report on Monday, September 30th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $16.14.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.